Acute myeloid leukemia (AML) is a complex disease that has proven incredibly difficult to treat with little improvement in long-term disease-free survival over the last several decades. In the past five years, a number of novel agents have been FDA approved for the treatment of AML. The understanding of novel mechanisms which can be therapeutically targeted for the treatment of AML continues to expand rapidly. This has lead to an increasing number of clinical trials in the treatment of AML as well as in the area of maintenance therapy after intensive induction or consolidative transplantation.
The goal of this Research Topic is to explore novel pathways in AML which can be exploited for therapy of either upfront or relapse/refractory AML as well as in the maintenance setting. An area of specific interest to be explored in this Research Topic is targeted maintenance therapy post allogeneic transplantation.
Subtopics of interests include but not limited to:
- Identifications of novel pathways for targeted therapies for AML: upfront, relapsed/refractory/ post-transplant maintenance.
- Combinational therapeutic strategies with chemotherapeutic, radiotherapeutic immunotherapeutic, targeted agents for AML.
- Pharmacology, preclinical or clinical studies of novel targeted drugs for AML.
Manuscripts including novel research and reviews are welcome.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Acute myeloid leukemia (AML) is a complex disease that has proven incredibly difficult to treat with little improvement in long-term disease-free survival over the last several decades. In the past five years, a number of novel agents have been FDA approved for the treatment of AML. The understanding of novel mechanisms which can be therapeutically targeted for the treatment of AML continues to expand rapidly. This has lead to an increasing number of clinical trials in the treatment of AML as well as in the area of maintenance therapy after intensive induction or consolidative transplantation.
The goal of this Research Topic is to explore novel pathways in AML which can be exploited for therapy of either upfront or relapse/refractory AML as well as in the maintenance setting. An area of specific interest to be explored in this Research Topic is targeted maintenance therapy post allogeneic transplantation.
Subtopics of interests include but not limited to:
- Identifications of novel pathways for targeted therapies for AML: upfront, relapsed/refractory/ post-transplant maintenance.
- Combinational therapeutic strategies with chemotherapeutic, radiotherapeutic immunotherapeutic, targeted agents for AML.
- Pharmacology, preclinical or clinical studies of novel targeted drugs for AML.
Manuscripts including novel research and reviews are welcome.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
